Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...
With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...
President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...
The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...
The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will ...
Acelyrin (NASDAQ:SLRN) stock in focus as the company adopts a poison pill to counter rapid stock acquisition by Tang Capital Partners. Read more here.
The death of a woman who was partially paralyzed in the Columbine High School shooting has been ruled a homicide, raising the ...
Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.
The companies confirmed on Monday they are in discussions about a combination in which QXO would acquire Beacon for $124.35 ...
Congress has approved a stopgap bill to fund the federal government through September 30 and avert a shutdown ahead of a ...
Republicans say their spending bill would let Trump defund whatever projects he wants. Chuck Schumer and Senate Dems are expected to help advance it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback